Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.48 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6833337 | 0.94 | RXFP1 (0.45) | RXFP1PARP14PPARGPPARDPPARA | |
| SCHEMBL6834504 | 0.90 | LMNA (0.47) | RXFP1PARP14MEN1KMT2A | |
| SCHEMBL6833973 | 0.89 | PARP14 (0.42) | RXFP1PARP14MAPTKCNQ2 | |
| SCHEMBL6833821 | 0.88 | NHERF1 (0.43) | PARP14MEN1KMT2AKCNQ2 | |
| SCHEMBL6833157 | 0.88 | PARP14 (0.42) | PARP14MEN1KMT2AKCNQ2MAPK8 | |
| SCHEMBL6833683 | 0.87 | NR1H4 (0.48) | PPARGPPARDPPARANR1H4 | |
| SCHEMBL6835671 | 0.87 | LMNA (0.39) | RXFP1PARP14MAPT | |
| SCHEMBL6834298 | 0.87 | MEN1 (0.44) | PARP14PPARGPPARDPPARANR1H4 | |
| SCHEMBL6833069 | 0.85 | POLB (0.48) | PARP14PPARDMAPTMEN1KMT2A | |
| SCHEMBL6835743 | 0.85 | MEN1 (0.42) | RXFP1NR1H4MEN1KMT2ACDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | RXFP1 3523/4885PARP14 2395/4885PPARG 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.